401 related articles for article (PubMed ID: 16034459)
21. Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir.
Wang S; Qi J; Smith M; Link CJ
Cancer Gene Ther; 2002 Jan; 9(1):1-8. PubMed ID: 11916238
[TBL] [Abstract][Full Text] [Related]
22. HSV-1-based amplicon vectors: design and applications.
Epstein AL
Gene Ther; 2005 Oct; 12 Suppl 1():S154-8. PubMed ID: 16231049
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of Th2 responses to replicative herpes simplex virus type 1 vectors by immunomodulative chemotherapy.
Peltoniemi J; Broberg EK; Nygårdas M; Erälinna JP; Waris M; Hukkanen V
Int Immunopharmacol; 2006 May; 6(5):817-29. PubMed ID: 16546713
[TBL] [Abstract][Full Text] [Related]
24. Efficient and non-toxic gene transfer to cardiomyocytes using novel generation amplicon vectors derived from HSV-1.
Ferrera R; Cuchet D; Zaupa C; Revol-Guyot V; Ovize M; Epstein AL
J Mol Cell Cardiol; 2005 Jan; 38(1):219-23. PubMed ID: 15623439
[TBL] [Abstract][Full Text] [Related]
25. Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons.
Müller L; Saydam O; Saeki Y; Heid I; Fraefel C
J Virol Methods; 2005 Jan; 123(1):65-72. PubMed ID: 15582700
[TBL] [Abstract][Full Text] [Related]
26. Efficient cotransduction of tumors by multiple herpes simplex vectors: implications for tumor vaccine production.
Karpoff HM; Kooby D; D'Angelica M; Mack J; Presky DH; Brownlee MD; Federoff H; Fong Y
Cancer Gene Ther; 2000 Apr; 7(4):581-8. PubMed ID: 10811476
[TBL] [Abstract][Full Text] [Related]
27. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Zhang J; Frolov I; Russell SJ
J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
[TBL] [Abstract][Full Text] [Related]
28. Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep(+) hybrid amplicon vector.
Bakowska JC; Di Maria MV; Camp SM; Wang Y; Allen PD; Breakefield XO
Gene Ther; 2003 Sep; 10(19):1691-702. PubMed ID: 12923568
[TBL] [Abstract][Full Text] [Related]
29. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
30. Discordance between expression and genome transfer titering of HSV amplicon vectors: recommendation for standardized enumeration.
Bowers WJ; Howard DF; Federoff HJ
Mol Ther; 2000 Mar; 1(3):294-9. PubMed ID: 10933945
[TBL] [Abstract][Full Text] [Related]
31. Targeting HSV amplicon vectors.
Grandi P; Spear M; Breakefield XO; Wang S
Methods; 2004 Jun; 33(2):179-86. PubMed ID: 15121173
[TBL] [Abstract][Full Text] [Related]
32. Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector.
Oehmig A; Cortés ML; Perry KF; Sena-Esteves M; Fraefel C; Breakefield XO
Gene Ther; 2007 Jul; 14(14):1078-91. PubMed ID: 17460718
[TBL] [Abstract][Full Text] [Related]
33. Genetic engineering of herpes simplex virus and vector genomes carrying loxP sites in cells expressing Cre recombinase.
Logvinoff C; Epstein AL
Virology; 2000 Feb; 267(1):102-10. PubMed ID: 10648187
[TBL] [Abstract][Full Text] [Related]
34. Hybrid herpes simplex virus/Epstein-Barr virus amplicon viral vectors confer enhanced transgene expression in primary human tumors and human bone marrow-derived mesenchymal stem cells.
Sia KC; Chong WK; Ho IA; Yulyana Y; Endaya B; Huynh H; Lam PY
J Gene Med; 2010 Oct; 12(10):848-58. PubMed ID: 20963807
[TBL] [Abstract][Full Text] [Related]
35. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.
Saeki Y; Fraefel C; Ichikawa T; Breakefield XO; Chiocca EA
Mol Ther; 2001 Apr; 3(4):591-601. PubMed ID: 11319922
[TBL] [Abstract][Full Text] [Related]
36. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
Chan T; Sami A; El-Gayed A; Guo X; Xiang J
Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
[TBL] [Abstract][Full Text] [Related]
37. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice.
Willis RA; Bowers WJ; Turner MJ; Fisher TL; Abdul-Alim CS; Howard DF; Federoff HJ; Lord EM; Frelinger JG
Hum Gene Ther; 2001 Oct; 12(15):1867-79. PubMed ID: 11589829
[TBL] [Abstract][Full Text] [Related]
38. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.
Hoffmann D; Wildner O
Cancer Gene Ther; 2007 Jul; 14(7):627-39. PubMed ID: 17479104
[TBL] [Abstract][Full Text] [Related]
39. Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice.
Cui FD; Asada H; Jin ML; Kishida T; Shin-Ya M; Nakaya T; Kita M; Ishii M; Iwai M; Okanoue T; Imanishi J; Mazda O
Gene Ther; 2005 Jan; 12(2):160-8. PubMed ID: 15470476
[TBL] [Abstract][Full Text] [Related]
40. Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.
Grant KG; Krisky DM; Ataai MM; Glorioso JC
Biotechnol Bioeng; 2009 Mar; 102(4):1087-97. PubMed ID: 18828174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
